Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tamsulosin hydrochloride
Drug ID BADD_D02114
Description Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common.[Label] It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy.[Label] Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow.[Label] Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.[A178351] Tamsulosin was first approved by the FDA on April 15, 1997.[L6238]
Indications and Usage Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.[Label] Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.[A178339,L6259]
Marketing Status approved; investigational
ATC Code G04CA02
DrugBank ID DB00706
KEGG ID D01024
MeSH ID D000077409
PubChem ID 5362376
TTD Drug ID D05MBZ
NDC Product Code 73750-099; 50090-5553; 65841-695; 67296-1319; 67296-1850; 68071-2561; 68788-7050; 70518-2052; 70934-092; 0781-2076; 49629-011; 62331-024; 60760-450; 67296-1803; 68382-132; 72603-115; 12838-2788; 65129-2074; 65841-118; 33342-159; 43063-264; 58118-0598; 61919-703; 63187-358; 67877-450; 70518-2541; 71335-0398; 55700-670; 63739-567; 71205-217; 71335-0711; 43063-725; 55154-7649; 67296-1155; 82009-025; 43579-011; 65862-298; 0024-5837; 57237-014; 60760-598; 65862-598; 67296-1739; 68071-4443; 51655-832; 68071-1934; 68071-3467; 71335-1538; 53069-0860; 68022-7005; 43353-019; 63187-371; 63187-469; 70518-1417; 70934-969; 71205-748; 43353-013; 62756-160; 63629-8135; 64679-516; 68084-299; 70518-0179; 71335-1784; 53296-0073; 16714-713; 43063-947; 68071-2859; 68788-7780; 71205-688; 0615-8055; 0904-6401; 17511-118; 53747-018; 50268-740; 0228-2996
UNII 11SV1951MR
Synonyms Tamsulosin | LY 253352 | LY-253352 | Tamsulosin Hydrochloride | 5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide | Flomax | YM 617 | YM-617
Chemical Information
Molecular Formula C20H29ClN2O5S
CAS Registry Number 106463-17-6
SMILES CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Arrhythmia02.03.02.001---
Asthenia08.01.01.001---
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Constipation07.02.02.001--
Cough22.02.03.001--
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dyspnoea02.11.05.003; 22.02.01.004--
Ejaculation disorder21.03.01.002--
Gravitational oedema02.05.04.014; 08.01.07.005---
Headache17.14.01.001--
Hypotension24.06.03.002--
Infection11.01.08.002---
Insomnia17.15.03.002; 19.02.01.002--
Libido decreased19.08.03.001; 21.03.02.005--
Nausea07.01.07.001--
Palpitations02.11.04.012--
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
Pruritus23.03.12.001--
Pupillary disorder06.05.03.008; 17.02.11.006---
Rash23.03.13.001---
Rhinitis11.01.13.004; 22.07.03.006--
Sinusitis11.01.13.005; 22.07.03.007--
Skin exfoliation23.03.07.003---
Somnolence17.02.04.006; 19.02.05.003--
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Tachycardia02.03.02.007---
The 1th Page    1 2    Next   Last    Total 2 Pages